- Home
- SJT vs GNLX Comparison
SJT vs GNLX Comparison
Compare SJT & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SJT | GNLX |
|---|---|---|
| Founded | 1980 | 2001 |
| Country | United States | United States |
| Employees | 495 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.7M | 133.0M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | SJT | GNLX |
|---|---|---|
| Price | $3.11 | $2.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | ★ 275.5K | 189.2K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.85 | $2.29 |
| 52 Week High | $6.61 | $8.54 |
Technical Indicators
Market Signals| Indicator | SJT | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 38.32 | 54.39 |
| Support Level | N/A | $2.36 |
| Resistance Level | $4.66 | $3.03 |
| Average True Range (ATR) | 0.19 | 0.18 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 38.83 | 76.98 |
Price Performance
Historical ComparisonAbout SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.